lembrando quando eu tive a ideia de usar a necessaire makeup da gocase como bolsinha de carregar esteto e tal (há 3 anos), influenciei amigas e agora eles anunciam com esse fim ✨
Visionária
eu tenho misofonia não é um segredo e sei q é um problema totalmente meu mas jurooo q não tô conseguindo não me irritar com o barulho de ar pingando aqui no meu prédio, toda noite essa bosta 🥲
The PHQ-9 is one of the most widely used depression screening tools in the world.
It's used in primary care offices, hospitals, schools, universities, workplace wellness programs, and mental health clinics. Millions of people have completed it. Many have received a depression diagnosis based, at least in part, on their score.
Most people assume the PHQ-9 emerged from a purely scientific effort to improve the identification of depression.
The actual story is more complicated.
In the early 1990s, Pfizer was preparing to market Zoloft. At the time, severe clinical depression was generally viewed as a relatively uncommon condition, and many primary care physicians were hesitant to diagnose and treat it.
Mental health assessments were complicated. They required time, clinical judgment, and an understanding of a person's life circumstances. Most family physicians didn't receive extensive psychiatric training and many were uncomfortable making psychiatric diagnoses.
This presented a problem.
If antidepressants were going to reach a much larger population, depression had to become easier to identify within primary care.
The solution was a brief screening questionnaire.
The idea for what eventually became the PHQ-9 originated with Pfizer marketing executive Howard Kroplick. The goal was straightforward: create a simple tool that could be administered during routine office visits and help physicians identify potential depression quickly and efficiently.
Over time, the PHQ-9 became embedded throughout healthcare.
The problem isn't that the questionnaire asks about symptoms associated with depression. The problem is that the symptoms it measures are not unique to depression.
Feeling down.
Loss of interest.
Trouble sleeping.
Fatigue.
Difficulty concentrating.
Changes in appetite.
These experiences certainly occur in depressive disorders. They also occur during grief, divorce, job loss, financial hardship, chronic illness, burnout, loneliness, and countless other painful but normal human experiences.
A questionnaire can count symptoms.
It cannot understand context.
It cannot tell whether someone is mourning the death of a spouse, struggling through a difficult life transition, or suffering from a depressive disorder.
That distinction requires a conversation.
It requires clinical judgment.
It requires understanding a person's history, relationships, circumstances, and meaning-making processes.
When we reduce emotional suffering to a checklist, we risk confusing normal human responses to adversity with psychiatric pathology.
This matters because screening tools do more than measure symptoms.
They shape how clinicians think.
They shape how patients understand themselves.
And they influence who receives a diagnosis, who receives medication, and how society defines mental illness.
The question is not whether depression exists.
The question is whether we have allowed a marketing-driven framework to expand the boundaries of diagnosis in ways that blur the distinction between clinical disorder and ordinary human suffering.
The history of the PHQ-9 deserves far more attention than it receives.
Most people have never been told this story.
They should be.
Read the full article and decide for yourself. 🔗in first comment
tengo una coleguita q cortei relações pela falta de consideração que religiosamente entra no meu perfil do tiktok… sendo q eu posto uma coisa em quase nunca…
se vcs soubessem quanta gente está buscando uma forma de se aposentar por invalidez com 50 e poucos anos e não tem critério clínico algum… (sim, claramente um problema social)
quem fala:
Aerolin = preguiçoso
Salbutamol = dedicado
Tazocin= porco q aprendeu de orelhada
Piperacilina-tazobactam= confiável
Rocefin = bate na mãe OU tem mais q 50 anos
Ceftriaxona= querido
Pessoa que fala a classe farmacológica= pode bater em mim
eu amo quando eu to blablabla e a pessoa escuta meu blablabla como se nao fosse um blablabla e sim como se fosse algo mt importante e responde meu blablabla